← Evidence map

ArticleClinical and molecular hepatology2026

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease".

May Xuan Goh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease". | OpenQuestion